European Heart Journal最新文献

{"title":"Weekly Journal Scan: from TRICk to treat—the first evidence of a clinical outcome benefit with transcatheter tricuspid valve intervention","authors":"Daniela Pedicino,Rocco Vergallo","doi":"10.1093/eurheartj/ehag780","DOIUrl":"https://doi.org/10.1093/eurheartj/ehag780","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":"18 1","pages":""},"PeriodicalIF":39.3,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149087965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atrial fibrillation density and stroke risk: a promising advance that now needs predictive validation","authors":"Lifeng Liang","doi":"10.1093/eurheartj/ehag548","DOIUrl":"https://doi.org/10.1093/eurheartj/ehag548","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":"166 1","pages":""},"PeriodicalIF":39.3,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149087969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carotid artery stenting in asymptomatic disease: a new paradigm.","authors":"Marco Roffi, Alison Halliday, Alberto Cremonesi","doi":"10.1093/eurheartj/ehag195","DOIUrl":"10.1093/eurheartj/ehag195","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":"5306-5308"},"PeriodicalIF":45.3,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147510828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FFR-guided revascularization in patients undergoing TAVI: insights on the FAITAVI trial.","authors":"Flavio L Ribichini, Gabriele Pesarini, Giuseppe Tarantini","doi":"10.1093/eurheartj/ehag259","DOIUrl":"10.1093/eurheartj/ehag259","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":"5320-5321"},"PeriodicalIF":45.3,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147987173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Leaders in cardiology: Donna Fitzsimons.","authors":"Judith Ozkan","doi":"10.1093/eurheartj/ehag347","DOIUrl":"10.1093/eurheartj/ehag347","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":"5228-5229"},"PeriodicalIF":45.3,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148162416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weekly Journal Scan: Expanding the therapeutic options for adolescents with obstructive hypertrophic cardiomyopathy","authors":"Daniela Pedicino,Giovanna Liuzzo","doi":"10.1093/eurheartj/ehag778","DOIUrl":"https://doi.org/10.1093/eurheartj/ehag778","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":"5 1","pages":""},"PeriodicalIF":39.3,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149092290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Training the diaphragm as a pillar of cardiac rehabilitation in heart failure","authors":"Ioannis D Laoutaris,Athanasios Dritsas,Stamatis Adamopoulos","doi":"10.1093/eurheartj/ehag789","DOIUrl":"https://doi.org/10.1093/eurheartj/ehag789","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":"13 1","pages":""},"PeriodicalIF":39.3,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149087961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep vein thrombosis exacerbated by syndecan-4 shedding and piezo1-dependent endothelial-mesenchymal transition","authors":"Ke Chen,Zhen-Zhen Chen,Jin-Wei Tian,Jun-Zhuo Wang,Lun Xiao,Hai-Zeng Zhang,Wen-Bin Wang,Dong-Ming Zhou,Xiao-Qiang Li,Jun Xie,Wen-Dong Li","doi":"10.1093/eurheartj/ehag775","DOIUrl":"https://doi.org/10.1093/eurheartj/ehag775","url":null,"abstract":"Abstract Background and Aims Deep vein thrombosis (DVT) remains a major health burden with incompletely understood mechanisms and limited therapeutic options. This study aims to investigate the role of key molecules in DVT and to explore the feasibility of treatment strategies based on this mechanism. Methods Plasma proteomic profiling (LC-MS/MS) was performed on DVT patients and healthy controls, identifying syndecan-4 (SDC4) as a differentially expressed protein. Functional investigations utilized SDC4 knockout mice, endothelial cell (EC)-specific lineage tracing models, and single-cell RNA sequencing to assess endothelial-to-mesenchymal transition (EndMT) during DVT progression. In vitro EndMT models were established in human umbilical vein endothelial cells. Protein interactions were confirmed by co-immunoprecipitation. Piezo1 was pharmacologically inhibited in vivo, and network pharmacology was used to seek a potential therapeutic agent. Results SDC4 levels were elevated in DVT patients. SDC4 deficiency exacerbated thrombus formation and promoted EndMT, as evidenced by reduced EC markers and increased mesenchymal markers. Single-cell sequencing revealed a specific EC subpopulation (C1) driving EndMT, with Piezo1 identified as a downstream mediator of SDC4. Co-IP confirmed direct SDC4–Piezo1 interaction. Piezo1 upregulation activated the PI3K/Akt pathway, Piezo1 knockdown attenuated EndMT and reduced thrombus burden. Quercetin directly bound Piezo1, reduced its expression in a dose-dependent manner, and significantly decreased thrombus size in DVT mice. Conclusions SDC4 shedding exacerbates DVT by promoting Piezo1-dependent EndMT via PI3K/Akt signalling. Quercetin shows therapeutic potential as a Piezo1 inhibitor.","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":"1 1","pages":""},"PeriodicalIF":39.3,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149087967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A 17-year journey of a first-generation drug-eluting stent: the extreme paradox of plaque rupture and arrested arterial healing.","authors":"Hidekazu Aoyama, Shimpei Tominaga, Ryosuke Kametani","doi":"10.1093/eurheartj/ehag470","DOIUrl":"10.1093/eurheartj/ehag470","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":"5322"},"PeriodicalIF":45.3,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148257955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Semaglutide, independent of weight loss, attenuates cardiac and hepatic remodelling in experimental heart failure with preserved ejection fraction","authors":"Mahmoud H Elbatreek,Zhen Li,Xiaoman Yu,Natalie D Gehred,Tatiana Gromova,Jingshu Chen,Miguel Huerta,Naoto Muraoka,Martin Borch Jensen,Vinay Kartha,Chris Carrico,Timothy D Allerton,Xinheng Zhang,Hsin-Jung R Yang,Michael E Bowdish,Sanjiv J Shah,Kathleen C Woulfe,Timothy A McKinsey,Edwin Yoo,David J Polhemus,Thomas M Vondriska,David J Lefer,Traci T Goodchild","doi":"10.1093/eurheartj/ehag732","DOIUrl":"https://doi.org/10.1093/eurheartj/ehag732","url":null,"abstract":"Abstract Background and Aims Heart failure with preserved ejection fraction (HFpEF) remains a significant therapeutic challenge. While GLP-1 receptor agonists (GLP-1RAs) show clinical promise, it remains unknown if their benefits are driven solely by weight loss or involve weight loss-independent mechanisms. We investigated the weight loss-independent effects of semaglutide in two preclinical models of cardiometabolic HFpEF: the ZSF1 Obese rat and the Göttingen HFpEF minipig. Methods Male ZSF1 Obese rats (n = 12/group) and female Göttingen minipigs with ‘two-hit’ induced HFpEF (early intervention: n = 5/group; delayed intervention: n = 4/group) were treated with semaglutide at doses empirically determined to be non-weight-loss inducing. Comprehensive assessments included invasive hemodynamic (LVEDP, PCWP), echocardiography, and histological quantification of fibrosis and lipid burden. Delayed intervention utilized Cardiac MRI to quantify subcutaneous and ectopic fat depots. In rats, advanced multi-omics (NULISA plasma proteomics, single-cell RNA sequencing and tissue proteomics) were utilized to explore molecular mechanisms. Results In ZSF1 Obese rats, semaglutide significantly improved diastolic function (reducing LVEDP by ∼60%) and attenuated cardiac hypertrophy (by ∼30%), interstitial fibrosis, and cardiac lipid deposition in the absence of a significant weight loss. These functional benefits were conserved in the minipig HFpEF model, where treatment attenuated cardiac hypertrophy, left ventricular E/e′, normalized pulmonary capillary wedge pressure (PCWP) and reversed advanced hepatic bridging fibrosis. Delayed intervention in established HFpEF minipigs reversed diastolic dysfunction and significantly reduced ectopic lipid depots (intramyocardial, epicardial, and hepatic fat) without affecting subcutaneous fat or total body weight. Mechanistically, multi-omics analyses in the rat heart revealed that these benefits were driven by suppression of pro-fibrotic and hypertrophic signals and up-regulation of branched-chain amino acid (BCAA) catabolism and fatty acid oxidation pathways in cardiomyocytes. Conclusions Semaglutide attenuates cardiac and hepatic remodelling in preclinical models of obesity-associated cardiometabolic HFpEF in the absence of profound weight loss. The conservation of these effects across male rodents and female swine supports their translational relevance, while future studies are needed to define dose equivalence and confirm GLP-1 receptor engagement in cardiac and hepatic tissues. These findings support further mechanistic investigation of weight loss-independent GLP-1 receptor agonist signalling in this HFpEF phenotype.","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":"24 1","pages":""},"PeriodicalIF":39.3,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149087964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}